NI201900050A - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- NI201900050A NI201900050A NI201900050A NI201900050A NI201900050A NI 201900050 A NI201900050 A NI 201900050A NI 201900050 A NI201900050 A NI 201900050A NI 201900050 A NI201900050 A NI 201900050A NI 201900050 A NI201900050 A NI 201900050A
- Authority
- NI
- Nicaragua
- Prior art keywords
- magl inhibitors
- compositions
- magl
- useful
- compounds
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- CWPIBZMCMRNFHK-UHFFFAOYSA-N piperazin-1-ium;carbamate Chemical class NC(O)=O.C1CNCCN1 CWPIBZMCMRNFHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423095P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201900050A true NI201900050A (es) | 2019-10-30 |
Family
ID=62107273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201900050A NI201900050A (es) | 2016-11-16 | 2019-05-16 | Inhibidores de magl |
Country Status (27)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2800565T1 (sl) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Karbamatne spojine in metode izdelave in uporabe le-teh |
| MX2017014344A (es) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| ES2892952T3 (es) | 2016-09-19 | 2022-02-07 | H Lundbeck As | Carbamatos de piperazina como moduladores del MAGL y/o ABHD6 y su uso |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| AU2017361257B2 (en) | 2016-11-16 | 2022-02-10 | H. Lundbeck A/S. | Crystalline forms of a MAGL inhibitor |
| BR112020004101A2 (pt) | 2017-08-29 | 2020-09-24 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| BR112020008762A2 (pt) * | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas amino-tiazol substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
| EA202092586A1 (ru) | 2018-05-15 | 2021-03-10 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Ингибиторы magl |
| MX2022013224A (es) * | 2020-04-21 | 2022-11-14 | H Lundbeck As | Sintesis de un inhibidor de la monoacilglicerol lipasa. |
| TW202229255A (zh) | 2020-11-13 | 2022-08-01 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (US07794700-20100914-C00125.png) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
| EP0619804B1 (en) | 1991-11-27 | 1996-05-22 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| DE69408873T2 (de) | 1993-12-22 | 1998-07-09 | Shell Int Research | Verfahren zur herstellung von carbamaten |
| WO1997018196A1 (en) | 1995-11-15 | 1997-05-22 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| EP1218544B1 (en) | 1999-10-04 | 2009-06-03 | The University of Medicine and Dentistry of New Jersey | TAR RNA binding peptides |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
| BRPI0507499A (pt) | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 |
| EP1740547A1 (en) * | 2004-04-07 | 2007-01-10 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| JP2008521768A (ja) | 2004-12-23 | 2008-06-26 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用 |
| EP1836179B1 (en) | 2004-12-30 | 2015-05-06 | Janssen Pharmaceutica NV | Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| US20100234351A1 (en) | 2006-02-23 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Fused nitrogen-comprising heterocyclic compound |
| CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| WO2010009207A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as gpcr modulators |
| JP5576874B2 (ja) | 2008-11-14 | 2014-08-20 | ザ スクリプス リサーチ インスティテュート | モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 |
| WO2010111050A1 (en) | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| PL2497082T3 (pl) | 2009-11-03 | 2013-12-31 | Bayer Ip Gmbh | Fluorouretany jako dodatek w formulacji fotopolimerowej |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| SI2800565T1 (sl) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Karbamatne spojine in metode izdelave in uporabe le-teh |
| WO2013102431A1 (en) | 2012-01-06 | 2013-07-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN104379578B (zh) | 2012-03-19 | 2017-06-09 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| CN105517547A (zh) | 2013-07-03 | 2016-04-20 | 阿比德治疗公司 | 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途 |
| JP2018513119A (ja) * | 2015-03-18 | 2018-05-24 | アビデ セラピューティクス，インク． | ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法 |
| MX2017014344A (es) * | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| US10030020B2 (en) * | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
-
2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/ar unknown
- 2017-11-15 EA EA201991074A patent/EA201991074A1/ru unknown
- 2017-11-15 US US15/814,318 patent/US9981930B1/en active Active
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/en active Application Filing
- 2017-11-15 AR ARP170103183A patent/AR110088A1/es unknown
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/en active Active
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/pt not_active Application Discontinuation
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/ko unknown
- 2017-11-15 CR CR20190243A patent/CR20190243A/es unknown
- 2017-11-15 MA MA046860A patent/MA46860A/fr unknown
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/zh active Active
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/es unknown
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/ru not_active Application Discontinuation
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/es unknown
- 2017-11-15 ES ES17871883T patent/ES2908632T3/es active Active
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/ja active Active
- 2017-11-15 CA CA3043612A patent/CA3043612A1/en not_active Abandoned
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-16 TW TW106139750A patent/TW201831458A/zh unknown
-
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/es unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/es unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/es unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/es unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2019000150A1 (en) | 2020-10-05 |
| PH12019501102A1 (en) | 2019-08-19 |
| IL266550A (en) | 2019-07-31 |
| EP3541822A4 (en) | 2020-04-29 |
| MA46860A (fr) | 2019-09-25 |
| AU2017361250A1 (en) | 2019-05-30 |
| US20180134675A1 (en) | 2018-05-17 |
| CN110248947A (zh) | 2019-09-17 |
| CN110248947B (zh) | 2022-04-01 |
| BR112019009991A2 (pt) | 2019-08-27 |
| CL2019001335A1 (es) | 2019-10-04 |
| MX2019005771A (es) | 2019-12-05 |
| KR20190077087A (ko) | 2019-07-02 |
| EA201991074A1 (ru) | 2019-12-30 |
| CA3043612A1 (en) | 2018-05-24 |
| JP2020502047A (ja) | 2020-01-23 |
| AR110088A1 (es) | 2019-02-20 |
| US9981930B1 (en) | 2018-05-29 |
| CO2019005038A2 (es) | 2019-05-31 |
| DOP2019000121A (es) | 2019-09-30 |
| ECSP19035377A (es) | 2019-05-31 |
| EP3541822A1 (en) | 2019-09-25 |
| PE20191146A1 (es) | 2019-09-02 |
| JOP20190105A1 (ar) | 2019-05-09 |
| RU2019116514A (ru) | 2020-12-17 |
| CR20190243A (es) | 2019-06-26 |
| EP3541822B1 (en) | 2022-01-19 |
| ES2908632T3 (es) | 2022-05-03 |
| WO2018093946A1 (en) | 2018-05-24 |
| TW201831458A (zh) | 2018-09-01 |
| JP6987859B2 (ja) | 2022-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19035077A (es) | Inhibidores de magl | |
| ECSP19035377A (es) | Inhibidores de magl | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| NI202000080A (es) | Inhibidores de magl | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| ECSP19083923A (es) | Inhibidores pirazólicos de magl | |
| NI201900049A (es) | Inhibidores de la magl | |
| CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CL2019003397A1 (es) | Inhibidores pirazólicos de magl. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |